| (19) |
 |
|
(11) |
EP 2 333 549 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
02.11.2011 Bulletin 2011/44 |
| (43) |
Date of publication A2: |
|
15.06.2011 Bulletin 2011/24 |
| (22) |
Date of filing: 05.09.2005 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
|
Designated Extension States: |
|
HR |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
05786272.4 / 1922546 |
| (71) |
Applicant: GlaxoSmithKline Biologicals s.a. |
|
1330 Rixensart (BE) |
|
| (72) |
Inventors: |
|
- De Vleeschauwer, Isabel
1330 Rixensart (BE)
- Durant, Nathalie
1330 Rixensart (BE)
- Poolman, Jan
1330 Rixensart (BE)
- Weynants, Vincent
1330 Rixensart (BE)
|
| (74) |
Representative: Johnston, Caroline Louise et al |
|
GlaxoSmithKline
Corporate Intellectual Property (CN925.1)
980 Great West Road
Brentford
Middlesex TW8 9GS
Brentford
Middlesex TW8 9GS (GB) |
|
| |
|
| (54) |
SERUM BACTERICIDAL ASSAY FOR N. MENINGITIDIS SPECIFIC ANTISERA |
(57) The present invention relates to the field of Serum Bactericidal Activity (SBA) assays
for Gram negative bacteria, in particular
N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum
antibodies against meningococcus. In order to determine whether a subject or a population
is seropositive against invasive meningococcus the SBA test should ideally be both
sensitive and specific. The inventors have found the standard
N. meningitidis serotype A and W SBAs can be significantly improved in this regard.